Mind the trial gap: EU medicines agency launches plan to include women in drug research
The European Medicines Agency wants pharmaceutical developers to stop treating male data as the default in clinical trials.
By Aldo Verheyen · Filed Wednesday, 30 September 2026 · Last updated 19:20 CET
What happened
The European Medicines Agency (EMA)—the regulator responsible for evaluating and supervising pharmaceuticals across the European Union—has published a new strategic roadmap to address the longstanding underrepresentation of women in medicines development. For decades, drug research has routinely relied on predominantly male trial participants, treating female biology as an unwanted variable rather than half the population. The agency's roadmap sets out a framework to ensure pharmaceutical developers actively recruit women into clinical trials, analyze sex-specific differences in drug efficacy and side effects, and account for biological factors like hormonal cycles in early-stage research.
Why it matters
When clinical trials primarily test drugs on men, women end up taking treatments whose dosages and side-effect profiles were designed for different bodies. Sex differences significantly alter how medications are metabolized, making women statistically more likely to suffer adverse drug reactions. By pushing developers to balance their trial pools, the EMA aims to ensure that medicines sold across the bloc are proven safe and effective for everyone, rather than assuming male trial data applies universally.
The Brussels angle
EU agencies excel at producing comprehensive roadmaps, but turning policy advice into corporate behavior relies on the administrative authority of market access. The EMA does not run clinical trials itself, but it holds the keys to the EU single market for pharmaceuticals. To decode the fog: in Brussels terminology, a regulatory "roadmap" outlines official expectations and future guidelines. While not immediately a binding law, meeting these agency standards will become a crucial requirement for drugmakers seeking marketing authorization across all 27 member states.
What happens next
Pharmaceutical companies, clinical research organizations, and national health authorities across the EU will now adjust their research frameworks to align with the EMA's roadmap. The agency is expected to integrate these sex-specific trial standards into its scientific advice procedures and evaluation metrics for new drug applications.
Written from these sources
Facts are extracted from primary institutional material and written independently by The Gazette desk.
Brussels Correspondent · European Commission
Aldo VerheyenAldo Verheyen is The Gazette's Brussels Correspondent, covering the European Commission, its College and the art of the leaked draft. He has reported from the Berlaymont since 2019 and translates proposals into plain English before they become law.
More from Aldo Verheyen →The Brief
Brussels, decoded, every morning. What happened, what it means, one good dry joke.